Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × fluzoparib × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1 Breast 1

Conditions

Breast Neoplasms 5 Triple Negative Breast Neoplasms 4 Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Her-2 Negative Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Female Breast Cancer Patients 1 Breast Cancer Metastatic 1 Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

Capecitabine 47 Paclitaxel 41 Trastuzumab 33 Fulvestrant 28 pembrolizumab 24 Cyclophosphamide 23 Carboplatin 23 Letrozole 19 Gemcitabine 19 palbociclib 18 Docetaxel 18 exemestane 17 Lapatinib 16 Bevacizumab 15 eribulin 14 Everolimus 13 Magnetic Resonance Spectroscopy 12 Anastrozole 12 abemaciclib 11 Vinorelbine 11 Nivolumab 11 Cisplatin 11 trastuzumab deruxtecan 10 Tamoxifen 10 Albumin-Bound Paclitaxel 10 Specimen Handling 9 Radiotherapy 9 Doxorubicin 9 olaparib 8 Zoledronic Acid 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04355858 2022-07-26

MULAN

Fudan University

Phase 2 Unknown

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡